Merus NV Stock: Genmab Acquisition Deal at $97 Per Share Reshapes Biotech Investment Landscape for North American Investors

Genmab announced on September 29, 2025, its intent to acquire Merus NV (ISIN: NL0011375928, Nasdaq: MRUS) for $97.00 per share in cash, valuing the deal at approximately $8.0 billion. The tender offer is expected to close early in Q1 2026, offering premium value amid oncology pipeline advancements.

Merus NV, a clinical-stage oncology biotech firm listed on Nasdaq under ticker MRUS with ISIN NL0011375928, faces a transformative moment as Genmab A/S launches a $97.00 per share all-cash tender offer, valuing the company at around $8.0 billion. This deal, announced September 29, 2025, targets Merus's late-stage asset petosemtamab in Phase 3 trials, providing immediate liquidity for shareholders.

As of: 26.03.2026

By Elena Voss, Senior Biotech Editor at NorthStar Market Insights: Merus NV stands at the intersection of innovative antibody therapies and major M&A activity in oncology.

Acquisition Details and Strategic Fit

Genmab's wholly owned subsidiary will commence the tender offer for all Merus common shares, unanimously approved by both boards. The transaction aims to expand Genmab's late-stage pipeline, integrating petosemtamab, designated as a breakthrough therapy.

Merus specializes in bispecific antibodies using its Biclonics platform, targeting solid tumors and hematological malignancies. Petosemtamab, an EGFR-CD3 bispecific, shows promise in head and neck squamous cell carcinoma, now advancing to Phase 3.

This acquisition accelerates Genmab's shift to a wholly owned asset model, funded partly by prepayable debt with deleveraging targets under 3x gross leverage post-close. Genmab's 2025 guidance remains unchanged.

Merus NV's Business Model and Pipeline Strength

Founded in the Netherlands, Merus NV develops full-length human bispecific antibodies via its proprietary Biclonics technology. This platform enables multi-specific formats with natural effector functions, differentiating from fragment-based competitors.

Key assets include petosemtamab for solid tumors, partnered earlier but now central to the deal. Other candidates target multi-specific combinations for immuno-oncology, focusing on tumor-targeted T-cell activation.

Merus's strategy emphasizes internal development of differentiated candidates, supported by collaborations with major pharma. Revenue historically from milestones and royalties, with R&D driving value creation.

In Q4 2024 financials, released February 27, 2025, Merus provided updates underscoring pipeline momentum pre-acquisition announcement.

Oncology Sector Drivers and Competitive Landscape

The oncology biotech sector thrives on innovation in antibody therapies, with bispecifics gaining traction for precision targeting. Merus positions well amid demand for next-gen immunotherapies beyond PD-1 inhibitors.

Competitors like Amgen, Regeneron, and Roche advance similar modalities, but Merus's full-length Biclonics offer advantages in half-life and Fc functionality. Petosemtamab's breakthrough status signals regulatory favor.

Sector tailwinds include rising cancer incidence, aging populations, and U.S. market dominance in biotech funding. North American investors benefit from Nasdaq listing, easing access.

M&A activity surges as big pharma builds pipelines, with 2025 seeing multiple high-value deals. Genmab's move fits this trend, securing late-stage assets amid patent cliffs.

Investor Relevance for North American Markets

For U.S. and Canadian investors, MRUS shares on Nasdaq provide direct exposure to European biotech innovation. The $97 offer represents a substantial premium over historical levels, with 52-week high at $97.14 on December 19, 2025.

Pre-deal, shares traded around lower ranges, with 2025 year-end close at $15.47 after starting at $31.02, reflecting volatility typical in clinical biotechs.

Post-announcement, the deal offers cash exit at premium valuation, appealing for risk-averse portfolios. Tax implications favor U.S. holders via tender offer structure.

Genmab's Nasdaq listing (GMAB) ensures continued U.S. market presence, potentially unlocking synergies for North American stakeholders.

Risks and Open Questions Ahead

While approved by boards, the deal awaits shareholder tender and regulatory clearances, including antitrust review. Closure targeted early Q1 2026, but delays possible.

Financing risks involve debt levels, though Genmab commits to deleveraging. Integration challenges post-close could impact asset development timelines.

Pipeline risks persist: Phase 3 petosemtamab success not guaranteed, with clinical trial uncertainties common in oncology. Competitive pressures may intensify.

For non-tendering shareholders, potential squeeze-out if majority accepts. Market volatility around closure warrants monitoring.

What North American Investors Should Watch Next

Track tender offer commencement and progress toward early 2026 close. Regulatory filings with SEC and EU authorities will provide timelines.

Genmab's February 2026 outlook update may detail integration plans. Petosemtamab trial data readouts remain key, even under new ownership.

Monitor GMAB shares for acquisition-related moves. Broader biotech M&A trends influence valuation precedents.

Stay attuned to oncology sector catalysts, including FDA decisions on bispecifics, impacting comparable assets.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.